Immediate Impact

1 from Science/Nature 62 standout
Sub-graph 1 of 22

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
2024 Standout
3 intermediate papers

Works of Chikara Ogawa being referenced

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
2019
Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma
2016

Author Peers

Author Last Decade Papers Cites
Chikara Ogawa 669 353 136 158 48 942
Sang Jun Suh 630 577 100 192 47 1.1k
Xin Zhang 586 330 99 138 59 905
Kinya Okamoto 430 420 97 280 46 1.0k
Michela Emma Burlone 661 580 92 81 41 1.0k
Anna Pecorelli 649 655 105 114 43 1.1k
Khaled Zalata 353 376 80 126 60 908
Hirokazu Kawai 353 299 100 196 63 962
Sun Young Yim 459 441 93 217 73 929
Sumio Saito 491 392 236 124 65 1.1k
Kenneth M. Klein 276 216 61 158 41 851

All Works

Loading papers...

Rankless by CCL
2026